HOME >> BIOLOGY >> NEWS
Results from open-label Raptiva study suggest continued benefit with long-term treatment

Genentech, Inc. and XOMA Ltd. today announced preliminary results from an open-label, multicenter trial evaluating the long-term safety and tolerability of continuous RaptivaTM (efalizumab) treatment in patients with moderate-to-severe psoriasis.

"The findings from this important open-label study on the long-term safety and efficacy of Raptiva are very encouraging and further support Raptiva's potential to address the unmet medical need of patients with moderate-to-severe psoriasis," said Hal Barron M.D., FACC, Genentech's vice president, Medical Affairs.

Alice Gottlieb, M.D., director of the Clinical Research Center at the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey presented data for patients receiving continuous Raptiva treatment for one year following an initial three months of treatment. The data were presented on Saturday, March 22 at the 61st annual American Academy of Dermatology meeting being held in San Francisco.

Response Rates with Continued Raptiva Treatment

A total of 339 patients were enrolled in this continuing open-label, multicenter study. 41 percent of patients (140/339) achieved 75 percent or greater improvement in Psoriasis Area and Severity Index (PASI) scores (PASI 75) and 82 percent (278/339) achieved PASI 50 or greater improvement after 12 weeks of 2 mg/kg/week Raptiva therapy. Patients who achieved a PASI 50 score or OLS (Overall Lesion Severity scale) of clear, minimal or mild at week 12 were eligible to enter the continuous treatment period. Of the original 339 patients, 290 patients who met the entry criteria for the maintenance period entered the continuous treatment phase of the study. For each successive three-month period of treatment, dropouts during that cohort period were counted as non-responders for that cohort, but were excluded from the subsequent cohorts.

Starting from week 13, the wee
'"/>

Contact: Emmy Tsui
emmy.tsui@ketchum.com
646-935-4019
Ketchum
24-Mar-2003


Page: 1 2 3 4 5

Related biology news :

1. Results of pivotal study for GlaxoSmithKlines Valtrex published in New England Journal of Medicine
2. NASA Materials Conference Features Science Results, Experts on Technologies for Exploration
3. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
4. Encouraging Results In Preclinical Studies Of Parkinsons Disease Gene Therapy
5. Quicker Implementation Of Research Results
6. Results Of Poisoning Visible In Urine
7. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
8. New Gene Therapy Technique Results In Efficient Gene Delivery
9. False Security: You Cant Always Believe The Results Of A Genetic Test
10. Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps
11. Results Of Hog-Stress Study May Lead To Better Management Methods

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2019)... FRANCISCO (PRWEB) , ... February 01, 2019 , ... ... ISO 15189 Accreditation for Clinical Testing Laboratories by A2LA, which establishes requirements for ... an international standard. The laboratory is already CLIA-licensed as well as College of ...
(Date:1/24/2019)... ... January 23, 2019 , ... rHEALTH LLC, an innovative digital ... from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application ... (DMI). This application covers the addition of a length scale to hydrogel microparticles. ...
(Date:1/20/2019)... (PRWEB) , ... January 17, 2019 , ... ... regards to drug metabolism and distribution has been documented for many years. These ... or in terms of adverse event profiles in patients residing in different geographic ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... ... January 29, 2019 , ... K&R Negotiations announced today that Mladen Kresic, CEO ... event titled: Six Ways to Shorten the Sales Cycle : Reduce Complexity and ... the BrightTALK network. , Negotiation expert Kresic will discuss the realities of today’s ...
(Date:1/28/2019)... ... 2019 , ... Fragment-based lead discovery (FBLD) involves biophysical screening ... false positives can be problematic due to high levels of solvents and nonspecific ... highly sensitive to detect weak interactions. Nanomed , leading producer of graphene ...
(Date:1/21/2019)... ... January 21, 2019 , ... ... line, SporActiv™, for the industrial and institutional cleaning market. MDG’s SporActiv liquid and ... commercial cleaning needs. Applications include odor control, floor and tile cleaners, carpets, drains, ...
(Date:1/20/2019)... NEW YORK (PRWEB) , ... January 17, 2019 ... ... chain tracking and orchestration system software developer, and The Quick Life Science Group ... logistics orchestration platform. , The platform enables the global cell and gene therapy ...
Breaking Biology Technology:
Cached News: